TECLens' proven CXLens will provide patients with a comfortable, non-invasive alternative to the treatment of ectatic disorders
Image: TECLens completes enrolment for clinical study on Keratoconus treatment. Photo: Courtesy of Darko Stojanovic from Pixabay.
TECLens, a medical device manufacturer, today announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens ‘on-eye’ cross-linking system for corneal remodeling. Clinical trial results are anticipated in early 2020.
TECLens’ proven CXLens will provide patients with a comfortable, non-invasive alternative to the treatment of ectatic disorders. Unlike any other cross-linking system, CXLens does not require an eyelid speculum. The patient can relax during the therapy, with his or her eyes open or closed. The CXLens tracks precisely with the patient’s eye and head movement, so there are no targeting errors and no need for a technician to monitor the beam position during treatment.
Dr. Juan Batlle, the Principle Investigator on the study commented, “The CXLens device is easy to use and is well tolerated by my patients. For the first time I have been able to perform corneal collagen cross-linking with minimal to no discomfort following the procedure, and yet have been able to see significant improvement in both visual and refractive outcomes while stabilizing patients’ corneal ectasia.”
“We are very happy with how the system performed in Dr. Batlle’s hands. The TECLens platform should significantly increase clinical efficiency and procedure margin for physicians practicing corneal cross-linking, while providing a much more patient friendly procedure for patients,” said TECLens CEO, David Acker
Source: Company Press Release